CAPRICOR THERAPEUTICS INC. - COMMON STOCK

Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

09 May 2024 09:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences

08 May 2024 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13

06 May 2024 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

24 Apr 2024 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Upcoming Investor Conferences

21 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

06 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

29 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy

27 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

22 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization

20 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

24 Jan 2024 09:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

11 Dec 2023 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

14 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14

07 Nov 2023 09:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program

19 Oct 2023 16:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society

10 Oct 2023 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces $23 Million Registered Direct Offering

29 Sep 2023 07:35:51 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

29 Sep 2023 07:30:58 By Nasdaq GlobeNewswire

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

06 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

07 Aug 2023 16:05:00 By Nasdaq GlobeNewswire